Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 3

Metoprolol succinate extended release/hydrochlorothiazide combination tablets

Authors James W Hainer, Jennifer Sugg

Published 15 July 2007 Volume 2007:3(3) Pages 279—288

Download Article [PDF] 

James W Hainer, Jennifer Sugg

AstraZeneca LP, Wilmington, DE, USA

Abstract: Lowering elevated blood pressure (BP) with drug therapy reduces the risk for catastrophic fatal and nonfatal cardiovascular events such as stroke and myocardial infarction. Given the heterogeneity of hypertension as a disease, the marked variability in an individual patient’s BP response, and low response rates with monotherapy, expert groups such as the Joint National Committee (JNC) emphasize the value of combination antihypertensive regimens, noting that combinations, usually of different classes, have additive antihypertensive effects. Metoprolol succinate extended-release tablet is a beta-1 (cardio-selective) adrenoceptor-blocking agent formulated to provide controlled and predictable release of metoprolol. Hydrochlorothiazide (HCT) is a well-established diuretic and antihypertensive agent, which promotes natruresis by acting on the distal renal tubule. The pharmacokinetics, efficacy, and safety/tolerability of the antihypertensive combination tablet, metoprolol extended release hydrochlorothiazide, essentially reflect the well-described independent characteristics of each of the component agents. Not only is the combination product more effective than monotherapy with the individual components but the combination product allows a low-dose multidrug regimen as an alternative to high-dose monotherapy, thereby, minimizing the likelihood of dose-related side-effects.

Keywords: antihypertensive, blood pressure, cardiovascular disease, combination product

Download Article [PDF]